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Phosphoinositide 3’-kinase delta: turning off BCR signaling in 
Chronic Lymphocytic Leukemia.
By Julia Hoellenriegel and Jan A. Burger
The phosphoinositide 3-kinase (PI3K) signaling 
pathway is involved in a wide variety of normal cellular 
processes including cell death and survival, migration, 
protein synthesis, and metabolism. PI3Ks are also 
commonly activated in human cancers [1], either by 
activating mutations of PI3K signaling modules, or by 
pathway activation after triggering of surface receptors.   
PIK3CA, the gene encoding the PI3K catalytic subunit 
(p110α),  PTEN  inactivation,  or  mutations  in  the  p85 
regulatory subunit are examples of activating PI3K 
mutations found in solid tumors. In contrast, leukemia 
and lymphoma cells do not harbor activating PI3K 
mutations [2], but nonetheless PI3Ks are constitutively 
activated, presumably due to activating signals from the 
microenvironment. In this context, PI3K signaling is 
now targeted in first clinical trials in patients with B cell 
malignancies, including Chronic Lymphocytic Leukemia 
(CLL),  which  represent  one  of  the  first  molecularly 
targeted therapies for B cell malignancies.
Interactions within neighbor stromal cells in tissue 
microenvironments (bone marrow, secondary lymphatic 
tissues) are necessary for maintenance and expansion of 
normal and malignant B cell, mediated by activation of 
various signaling pathways in the B cells, including B-cell 
receptor (BCR) signaling [3]. The BCR pathway recently 
emerged as a central pathway in the pathogenesis of several 
B-cell malignancies [4], including chronic lymphocytic 
leukemia (CLL) [5], and can be therapeutically targeted 
with small molecule inhibitors of BCR-associated kinases, 
inhibiting either Spleen tyrosine kinase (Syk), Bruton’s 
tyrosine kinase (Btk), or PI3K. PI3Ks play an essential, 
non-redundant role in BCR signaling, as demonstrated in 
a BCR deficient mouse model, in which PI3K signaling 
was able to rescue mature B cells [6]. Expression of the 
PI3Kδ isoform is largely restricted to hematopoietic cells, 
where it is involved in B-cell homeostasis and function, as 
demonstrated in mice with inactivating PI3K mutations. 
Such mice have reduced numbers of B1 and marginal 
zone  B  cells,  reduced  levels  of  immunoglobulins, 
respond poorly to immunization, and display defective 
BCR and CD40 signaling [7]. This restricted expression 
makes PI3Kδ an ideal therapeutic target in hematologic 
malignancies.  CAL-101,  the  first  p110δ  inhibitor  in 
clinical use [8], is currently explored in advanced-stage 
clinical trials in patients with B cell malignancies [9]. 
Recently,  we  characterized  the  effects  of  CAL-101  in 
CLL in a series of correlative laboratory studies [10]. We 
reported that CAL-101 thwarts CLL chemokine receptor 
function and migration beneath marrow stroma cells. 
Also,  CAL-101  disrupted  BCR  signaling,  life  support 
by nurselike cells, and BCR-dependent secretion of the 
chemokine CCL3 (MIP-1α) by CLL cells in vitro and in 
vivo in CLL patients receiving therapy with CAL-101. 
These findings are important for understanding the 
characteristic clinical activity of CAL-101 in CLL. After 
start of therapy with CAL-101, CLL patients typically 
experience rapid resolution of enlarged lymph nodes, 
along with a transient surge in blood lymphocyte counts. 
Then, oftentimes after weeks to months of therapy, 
lymphocyte counts gradually improve and normalize 
[9].  These  effects  are  explained  by  CAL-101-induced 
blockade of tissue anchors signals, the chemokine 
receptors, which normally retain CLL cells in the lymph 
glands (see Fig. 1). Later during therapy, the effects of 
CAL-101 on survival signaling become apparent, leading 
to the gradual decline in lymphocyte counts, and then 
many patients achieve remissions. Interestingly, even 
high-risk CLL patients, for example CLL patients with 
17p deletions, which are largely resistant to conventional 
CLL  therapies  [11],  respond  to  inhibitors  of  BCR-
associated kinases, such as CAL-101, and their response 
rates do not seem to substantially differ from lower-risk 
patients. What is also remarkable is that fact that Syk 
and Btk inhibitors cause similar clinical effects in CLL 
patients, early lymphocytosis and rapid lymph node 
shrinkage, suggesting that these BCR-associated kinases 
play similar roles for CLL cell migration, tissue homing, 
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of these new, targeted agents in the laboratory and in 
clinical  trials,  these  findings  are  already  changing  our 
understanding of disease biology, and likely will have a 
broad impact on treatments for patients with CLL, other 
B cell malignancies [12, 13], and autoimmune disorders 
[14] in the near-term future.
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